The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III

Launched by OTTAWA HOSPITAL RESEARCH INSTITUTE · Apr 29, 2021

Keywords

ClinConnect Summary

The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial, also known as the Thoracic POISE project, is a study aimed at improving care for patients with lung, gastric, and esophageal cancer who are having surgery to remove their tumors. The trial is focusing on two main issues: many patients experience complications during and after surgery, and they also worry about cancer coming back later on. This study wants to see if a more comprehensive approach that combines different types of care can help improve patients' overall quality of life, reduce these complications, and potentially extend their survival.

To participate in this trial, you need to be an adult who is eligible for surgery to completely remove lung, gastric, or esophageal cancer. However, certain patients, such as those with specific types of tumors or those receiving certain treatments, may not qualify. If you join the study, you can expect to receive careful monitoring and support throughout your surgical journey. This trial is currently recruiting participants, and it aims to bring together the best of traditional and complementary medicine to enhance patient care in a way that reflects real-world needs.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • • Adults eligible for complete resection of lung, gastric or esophageal cancer
• • Exclusion criteria
• • Small cell, carcinoid, or gastrointestinal stromal (GIST) tumours
• • Any wedge resections of lung cancer
• • History of cancer with active treatment in the last 3 years (not including superficial bladder cancer or non-melanoma skin cancer)
• • Patients currently receiving care guided by an ND or who have previously seen an ND in the last 3 months
• • Pregnant or breastfeeding women\*
• • Any reason which, in the opinion of the Principal Investigator (or delegate), would prevent the subject from participating in the study
• • Use of an investigational drug or participation in an investigational study within 30 days prior to starting the study